These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
KANSAS
|
45-4082531
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
100 Commercial Street, Atchison, Kansas
|
66002
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Page
|
|||
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
||
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
Quarter Ended
|
|
Year to Date Ended
|
||||||||||||
|
|
|
September 30,
2014 |
|
September 30,
2013 |
|
September 30,
2014 |
|
September 30,
2013 |
||||||||
|
Sales
|
|
$
|
83,966
|
|
|
$
|
80,709
|
|
|
$
|
254,451
|
|
|
$
|
253,134
|
|
|
Less: excise taxes
|
|
6,451
|
|
|
538
|
|
|
17,373
|
|
|
7,164
|
|
||||
|
Net sales
|
|
77,515
|
|
|
80,171
|
|
|
237,078
|
|
|
245,970
|
|
||||
|
Cost of sales (a)
|
|
70,204
|
|
|
79,356
|
|
|
214,658
|
|
|
232,645
|
|
||||
|
Gross profit
|
|
7,311
|
|
|
815
|
|
|
22,420
|
|
|
13,325
|
|
||||
|
Selling, general and administrative expenses
|
|
4,966
|
|
|
6,760
|
|
|
15,204
|
|
|
17,405
|
|
||||
|
Insurance recoveries
(Note 6)
|
|
(1,293
|
)
|
|
—
|
|
|
(1,223
|
)
|
|
—
|
|
||||
|
Other operating costs and losses on sale of assets
|
|
1
|
|
|
1
|
|
|
1
|
|
|
59
|
|
||||
|
Income (loss) from operations
|
|
3,637
|
|
|
(5,946
|
)
|
|
8,438
|
|
|
(4,139
|
)
|
||||
|
Interest expense, net
|
|
(199
|
)
|
|
(269
|
)
|
|
(615
|
)
|
|
(829
|
)
|
||||
|
Equity method investment earnings (loss)
|
|
1,621
|
|
|
(91
|
)
|
|
7,287
|
|
|
(962
|
)
|
||||
|
Income (loss) from continuing operations before income taxes
|
|
5,059
|
|
|
(6,306
|
)
|
|
15,110
|
|
|
(5,930
|
)
|
||||
|
Provision (benefit) for income taxes
|
|
(1,169
|
)
|
|
19
|
|
|
(1,002
|
)
|
|
44
|
|
||||
|
Net income (loss) from continuing operations
|
|
6,228
|
|
|
(6,325
|
)
|
|
16,112
|
|
|
(5,974
|
)
|
||||
|
Discontinued operations, net of tax
(Note 8)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,406
|
|
||||
|
Net income (loss)
|
|
6,228
|
|
|
(6,325
|
)
|
|
16,112
|
|
|
(4,568
|
)
|
||||
|
Other comprehensive income (loss), net of tax
|
|
(123
|
)
|
|
(111
|
)
|
|
202
|
|
|
(401
|
)
|
||||
|
Comprehensive income (loss)
|
|
$
|
6,105
|
|
|
$
|
(6,436
|
)
|
|
$
|
16,314
|
|
|
$
|
(4,969
|
)
|
|
Basic and diluted earnings (loss) per share
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Income (loss) from continuing operations
|
|
$
|
0.34
|
|
|
$
|
(0.37
|
)
|
|
$
|
0.89
|
|
|
$
|
(0.35
|
)
|
|
Income from discontinued operations
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.08
|
|
||||
|
Net income (loss)
|
|
$
|
0.34
|
|
|
$
|
(0.37
|
)
|
|
$
|
0.89
|
|
|
$
|
(0.27
|
)
|
|
Dividends and dividend equivalents per common share
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
0.05
|
|
|
$
|
0.05
|
|
|
(a)
|
Includes related party purchases of
$10,079
and
$702
for the quarters ended
September 30, 2014
and
2013
, respectively. Includes related party purchases of
$26,220
and
$5,494
for the year to date periods ended
September 30, 2014
and
2013
, respectively. See
Note 2. Equity Method Investments
.
|
|
|
|
September 30,
2014 |
|
December 31,
2013 |
||||
|
Current Assets
|
|
|
|
|
||||
|
Cash and cash equivalents
|
|
$
|
—
|
|
|
$
|
2,857
|
|
|
Receivables (less allowance for doubtful accounts: September 30, 2014 - $7; December 31, 2013 - $18)
|
|
31,550
|
|
|
27,821
|
|
||
|
Inventory
|
|
31,465
|
|
|
34,917
|
|
||
|
Prepaid expenses
|
|
1,435
|
|
|
848
|
|
||
|
Deferred income taxes
|
|
2,532
|
|
|
4,977
|
|
||
|
Refundable income taxes
|
|
225
|
|
|
466
|
|
||
|
Total current assets
|
|
67,207
|
|
|
71,886
|
|
||
|
Property and equipment
|
|
198,549
|
|
|
194,687
|
|
||
|
Less accumulated depreciation and amortization
|
|
(133,337
|
)
|
|
(124,443
|
)
|
||
|
Property and equipment, net
|
|
65,212
|
|
|
70,244
|
|
||
|
Equity method investments
|
|
14,364
|
|
|
7,123
|
|
||
|
Other assets
|
|
2,326
|
|
|
2,076
|
|
||
|
Total assets
|
|
$
|
149,109
|
|
|
$
|
151,329
|
|
|
Current Liabilities
|
|
|
|
|
|
|
||
|
Current maturities of long-term debt
|
|
$
|
2,598
|
|
|
$
|
1,557
|
|
|
Accounts payable
|
|
14,101
|
|
|
23,107
|
|
||
|
Accounts payable to affiliate, net
|
|
3,424
|
|
|
1,204
|
|
||
|
Accrued expenses
|
|
7,987
|
|
|
8,282
|
|
||
|
Total current liabilities
|
|
28,110
|
|
|
34,150
|
|
||
|
Long-term debt, less current maturities
|
|
8,329
|
|
|
3,611
|
|
||
|
Revolving credit facility
|
|
5,736
|
|
|
18,000
|
|
||
|
Deferred credit
|
|
4,259
|
|
|
3,925
|
|
||
|
Accrued retirement health and life insurance benefits
|
|
3,654
|
|
|
4,423
|
|
||
|
Other noncurrent liabilities
|
|
706
|
|
|
640
|
|
||
|
Deferred income taxes
|
|
1,318
|
|
|
4,977
|
|
||
|
Total liabilities
|
|
52,112
|
|
|
69,726
|
|
||
|
Commitments and Contingencies
(Note 4)
|
|
|
|
|
|
|
||
|
Stockholders’ Equity
|
|
|
|
|
|
|
||
|
Capital stock
|
|
|
|
|
|
|
||
|
Preferred, 5% non-cumulative; $10 par value; authorized 1,000 shares; issued and outstanding 437 shares
|
|
4
|
|
|
4
|
|
||
|
Common stock
|
|
|
|
|
|
|
||
|
No par value; authorized 40,000,000 shares; issued 18,115,965 shares at September 30, 2014 and December 31, 2013, 17,635,730 and 17,750,421 shares outstanding at September 30, 2014 and December 31, 2013, respectively
|
|
6,715
|
|
|
6,715
|
|
||
|
Additional paid-in capital
|
|
9,196
|
|
|
8,728
|
|
||
|
Retained earnings
|
|
81,891
|
|
|
66,686
|
|
||
|
Accumulated other comprehensive gain (loss), net of tax
|
|
198
|
|
|
(4
|
)
|
||
|
Treasury stock, at cost
|
|
|
|
|
|
|
||
|
Shares of
480,235
and 365,544 at September 30, 2014 and December 31, 2013, respectively
|
|
(1,007
|
)
|
|
(526
|
)
|
||
|
Total stockholders’ equity
|
|
96,997
|
|
|
81,603
|
|
||
|
Total liabilities and stockholders’ equity
|
|
$
|
149,109
|
|
|
$
|
151,329
|
|
|
|
|
Year to Date Ended
|
||||||
|
|
|
September 30,
2014 |
|
September 30,
2013 |
||||
|
Cash Flows from Operating Activities
|
|
|
|
|
||||
|
Net income (loss)
|
|
$
|
16,112
|
|
|
$
|
(4,568
|
)
|
|
Adjustments to Reconcile Net Income (Loss) to Net Cash Provided by Operating Activities:
|
|
|
|
|
|
|
||
|
Depreciation and amortization
|
|
9,202
|
|
|
8,955
|
|
||
|
Gain on sale of bioplastics manufacturing business
|
|
—
|
|
|
(1,453
|
)
|
||
|
Gains on property insurance recoveries
|
|
(1,223
|
)
|
|
—
|
|
||
|
Release of valuation allowance for deferred tax assets
|
|
(1,215
|
)
|
|
—
|
|
||
|
Share based compensation
|
|
588
|
|
|
970
|
|
||
|
Equity method investment (earnings) loss
|
|
(7,287
|
)
|
|
962
|
|
||
|
Changes in Operating Assets and Liabilities:
|
|
|
|
|
|
|
||
|
Restricted cash
|
|
—
|
|
|
12
|
|
||
|
Receivables, net
|
|
(3,729
|
)
|
|
3,529
|
|
||
|
Inventory
|
|
3,452
|
|
|
(342
|
)
|
||
|
Prepaid expenses
|
|
(587
|
)
|
|
(541
|
)
|
||
|
Refundable income taxes
|
|
241
|
|
|
16
|
|
||
|
Accounts payable
|
|
(8,188
|
)
|
|
(509
|
)
|
||
|
Accounts payable to affiliate, net
|
|
2,220
|
|
|
(3,491
|
)
|
||
|
Accrued expenses
|
|
(295
|
)
|
|
1,478
|
|
||
|
Deferred credit
|
|
334
|
|
|
(340
|
)
|
||
|
Accrued retirement health and life insurance benefits and other noncurrent liabilities
|
|
(456
|
)
|
|
(680
|
)
|
||
|
Other
|
|
(414
|
)
|
|
6
|
|
||
|
Net cash provided by operating activities
|
|
8,755
|
|
|
4,004
|
|
||
|
Cash Flows from Investing Activities
|
|
|
|
|
|
|
||
|
Additions to property and equipment
|
|
(4,920
|
)
|
|
(3,571
|
)
|
||
|
Proceeds from sale of bioplastics manufacturing business
|
|
—
|
|
|
2,797
|
|
||
|
Proceeds from property insurance recoveries
|
|
1,383
|
|
|
—
|
|
||
|
Proceeds from sale of property and other
|
|
4
|
|
|
—
|
|
||
|
Net cash used in investing activities
|
|
(3,533
|
)
|
|
(774
|
)
|
||
|
Cash Flows from Financing Activities
|
|
|
|
|
|
|
||
|
Purchase of treasury stock
|
|
(601
|
)
|
|
—
|
|
||
|
Payment of dividends
|
|
(907
|
)
|
|
(916
|
)
|
||
|
Principal payments on long-term debt
|
|
(1,162
|
)
|
|
(1,288
|
)
|
||
|
Proceeds from revolving credit facility
|
|
49,590
|
|
|
83,031
|
|
||
|
Payments on revolving credit facility
|
|
(54,933
|
)
|
|
(84,057
|
)
|
||
|
Loan fees incurred with borrowings
|
|
(66
|
)
|
|
—
|
|
||
|
Net cash used in financing activities
|
|
(8,079
|
)
|
|
(3,230
|
)
|
||
|
Decrease in cash and cash equivalents
|
|
(2,857
|
)
|
|
—
|
|
||
|
Cash and cash equivalents, beginning of year
|
|
2,857
|
|
|
—
|
|
||
|
Cash and cash equivalents, end of period
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
|
Capital
Stock
Preferred
|
|
Issued
Common
|
|
Additional
Paid-In
Capital
|
|
Retained
Earnings
|
|
Accumulated
Other
Comprehensive
Income (Loss)
|
|
Treasury
Stock
|
|
Total
|
||||||||||||||
|
Balance, December 31, 2013
|
|
$
|
4
|
|
|
$
|
6,715
|
|
|
$
|
8,728
|
|
|
$
|
66,686
|
|
|
$
|
(4
|
)
|
|
$
|
(526
|
)
|
|
$
|
81,603
|
|
|
Comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
|
Net income
|
|
—
|
|
|
—
|
|
|
—
|
|
|
16,112
|
|
|
—
|
|
|
—
|
|
|
16,112
|
|
|||||||
|
Change in pension plans (a)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(63
|
)
|
|
—
|
|
|
(63
|
)
|
|||||||
|
Change in post employment benefits (a)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
310
|
|
|
—
|
|
|
310
|
|
|||||||
|
Change in translation adjustment on non-consolidated foreign subsidiary, net of tax
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(45
|
)
|
|
—
|
|
|
(45
|
)
|
|||||||
|
Dividends and dividend equivalents declared and paid, net
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(907
|
)
|
|
—
|
|
|
—
|
|
|
(907
|
)
|
|||||||
|
Share-based compensation
|
|
—
|
|
|
—
|
|
|
468
|
|
|
—
|
|
|
|
|
|
120
|
|
|
588
|
|
|||||||
|
Common shares reacquired due to taxes derived from vesting of restricted stock and restricted stock units
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(601
|
)
|
|
(601
|
)
|
|||||||
|
Balance, September 30, 2014
|
|
$
|
4
|
|
|
$
|
6,715
|
|
|
$
|
9,196
|
|
|
$
|
81,891
|
|
|
$
|
198
|
|
|
$
|
(1,007
|
)
|
|
$
|
96,997
|
|
|
(a)
|
See
|
|
|
|
September 30,
2014 |
|
December 31,
2013 |
||||
|
Finished goods
|
|
$
|
9,707
|
|
|
$
|
11,355
|
|
|
Barreled distillate
|
|
9,834
|
|
|
10,310
|
|
||
|
Work in process
|
|
2,672
|
|
|
2,737
|
|
||
|
Raw materials
|
|
3,593
|
|
|
5,183
|
|
||
|
Maintenance materials
|
|
5,012
|
|
|
4,766
|
|
||
|
Other
|
|
647
|
|
|
566
|
|
||
|
Total
|
|
$
|
31,465
|
|
|
$
|
34,917
|
|
|
•
|
Level 1 - quoted prices in active markets for identical assets or liabilities accessible by the reporting entity.
|
|
•
|
Level 2 - observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
|
|
•
|
Level 3 - unobservable inputs for an asset or liability. Unobservable inputs should only be used to the extent observable inputs are not available.
|
|
|
|
Quarter Ended
|
|
Year to Date Ended
|
||||||||||||
|
|
|
September 30,
2014 |
|
September 30,
2013 |
|
September 30,
2014 |
|
September 30,
2013 |
||||||||
|
ICP’s Operating results:
|
|
|
|
|
|
|
|
|
||||||||
|
Net sales (a)
|
|
$
|
53,813
|
|
|
$
|
52,580
|
|
|
$
|
185,460
|
|
|
$
|
146,807
|
|
|
Cost of sales and expenses (b)
|
|
48,467
|
|
|
53,165
|
|
|
155,214
|
|
|
150,279
|
|
||||
|
Net income (loss)
|
|
$
|
5,346
|
|
|
$
|
(585
|
)
|
|
$
|
30,246
|
|
|
$
|
(3,472
|
)
|
|
(a)
|
Includes related party sales to MGPI of
$9,287
and
$110
for the quarters ended
September 30, 2014
and
2013
, respectively, and
$23,905
and
$3,510
for the year to date periods ended
September 30, 2014
and
2013
, respectively.
|
|
(b)
|
Includes depreciation and amortization of
$738
and
$1,171
for the quarters ended
September 30, 2014
and
2013
, respectively, and
$2,100
and
$3,511
for the year to date periods ended
September 30, 2014
and
2013
, respectively.
|
|
|
|
Quarter Ended
|
|
Year to Date Ended
|
||||||||||||
|
|
|
September 30,
2014 |
|
September 30,
2013 |
|
September 30,
2014 |
|
September 30,
2013 |
||||||||
|
ICP (a)
|
|
$
|
1,604
|
|
|
$
|
(135
|
)
|
|
$
|
7,192
|
|
|
$
|
(1,042
|
)
|
|
DMI (50% interest)
|
|
17
|
|
|
44
|
|
|
95
|
|
|
80
|
|
||||
|
|
|
$
|
1,621
|
|
|
$
|
(91
|
)
|
|
$
|
7,287
|
|
|
$
|
(962
|
)
|
|
(a)
|
The cumulative effect of the change in estimate for the year to date period ended
September 30, 2014
was a decrease in equity method investment earnings of
$1,882
, which reduced the joint venture investment earnings for the same period to
23.8 percent
. The joint venture investment earnings for the quarter ended
September 30, 2014
was
30 percent
, as well as for the quarter and year to date periods ended September 30, 2013.
|
|
|
|
September 30,
2014 |
|
December 31,
2013 |
||||
|
ICP (26.4% interest) (a)
|
|
$
|
13,845
|
|
|
$
|
6,653
|
|
|
DMI (50% interest)
|
|
519
|
|
|
470
|
|
||
|
|
|
$
|
14,364
|
|
|
$
|
7,123
|
|
|
(a)
|
The cumulative effect of the change in estimate was a decrease in equity interest in ICP of
$1,882
, which effectively reduced the Company's investment in ICP from
30 percent
to
26.4 percent
at
September 30, 2014
.
|
|
|
|
Quarter Ended
|
|
Year to Date Ended
|
||||||||||||
|
|
|
September 30,
2014 |
|
September 30,
2013 |
|
September 30,
2014 |
|
September 30,
2013 |
||||||||
|
Continuing Operations:
|
|
|
|
|
|
|
|
|
||||||||
|
Net income (loss) from continuing operations attributable to shareholders
|
|
$
|
6,228
|
|
|
$
|
(6,325
|
)
|
|
16,112
|
|
|
$
|
(5,974
|
)
|
|
|
Less: Amounts allocated to participating securities (nonvested shares and units)
(i)
|
|
268
|
|
|
—
|
|
|
692
|
|
|
—
|
|
||||
|
Net income (loss) from continuing operations attributable to common shareholders
|
|
$
|
5,960
|
|
|
$
|
(6,325
|
)
|
|
$
|
15,420
|
|
|
$
|
(5,974
|
)
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Discontinued Operations:
|
|
|
|
|
|
|
|
|
||||||||
|
Discontinued operations attributable to shareholders
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,406
|
|
|
Less: Amounts allocated to participating securities (nonvested shares and units)
(i)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
|
Discontinued operations attributable to common shareholders
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,406
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Share information:
|
|
|
|
|
|
|
|
|
||||||||
|
Basic weighted average common shares
(ii)
|
|
17,334,330
|
|
|
17,127,523
|
|
|
17,286,258
|
|
|
17,045,001
|
|
||||
|
Potential dilutive securities
(iii)
|
|
229
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
|
Diluted weighted average common shares
|
|
17,334,559
|
|
|
17,127,523
|
|
|
17,286,258
|
|
|
17,045,001
|
|
||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
Basic earnings (loss) per share
|
|
|
|
|
|
|
|
|
||||||||
|
Income (loss) from continuing operations
|
|
$
|
0.34
|
|
|
$
|
(0.37
|
)
|
|
$
|
0.89
|
|
|
$
|
(0.35
|
)
|
|
Income from discontinued operations
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.08
|
|
||||
|
Net income (loss)
(iv)
|
|
$
|
0.34
|
|
|
$
|
(0.37
|
)
|
|
$
|
0.89
|
|
|
$
|
(0.27
|
)
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Diluted earnings (loss) per share
|
|
|
|
|
|
|
|
|
||||||||
|
Income (loss) from continuing operations
|
|
$
|
0.34
|
|
|
$
|
(0.37
|
)
|
|
$
|
0.89
|
|
|
$
|
(0.35
|
)
|
|
Income from discontinued operations
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.08
|
|
||||
|
Net income (loss)
(iv)
|
|
$
|
0.34
|
|
|
$
|
(0.37
|
)
|
|
$
|
0.89
|
|
|
$
|
(0.27
|
)
|
|
(i)
|
Participating securities include
301,598
and
699,612
nonvested restricted shares for the quarters ended
September 30, 2014
and
2013
, respectively, as well as
476,149
and
413,764
restricted share units for the quarters ended
September 30, 2014
and
2013
, respectively.
|
|
(ii)
|
Under the two-class method, basic weighted average common shares exclude outstanding nonvested, participating securities consisting of restricted share awards of
301,598
and
699,612
for the quarters ended
September 30, 2014
and
2013
, respectively.
|
|
(iii)
|
Anti-dilutive shares related to stock options totaled
6,000
and
18,000
for the quarters ended
September 30, 2014
and
2013
, respectively, and
8,667
and
18,667
for the year to date periods ended
September 30, 2014
and
2013
, respectively. There were dilutive shares related to stock options totaling
4,000
and
0
for the quarters ended
September 30, 2014
and
2013
, respectively, and
1,333
and
1,333
for the year to date periods ended
September 30, 2014
and
2013
, respectively. The dilutive shares resulted in potential dilutive securities of
229
and
0
for the quarter and year to date periods ended
September 30, 2014
and potential dilutive securities of
0
and
0
for the quarter and year to date periods ended September 30,
2013
, respectively.
|
|
(iv)
|
See
Note 2. Equity Method Investments
for further discussion of earnings (loss) per share for the year to date period ended
September 30, 2014
.
|
|
•
|
Our current financial position and our historical results of operations for recent years. The Company generally considers cumulative pre-tax losses in the three-year period ending with the current quarter to be significant negative evidence regarding our future profitability. A pattern of objectively-measured recent financial reporting losses is heavily weighted as a source of negative evidence when relying upon projections of future taxable income to recover deferred tax assets. The Company also considers the historical and current financial trends in the recent years.
|
|
•
|
Sources of taxable income of the appropriate character. Future realization of deferred tax assets is dependent on projected taxable income of the appropriate character from our continuing operations. Future reversals of existing temporary differences are heavily-weighted sources of objectively verifiable positive evidence. Projections of future taxable income exclusive of reversing temporary differences are a source of positive evidence only when the projections are combined with a history of recent profits and current financial trends and can be reasonably estimated.
|
|
•
|
Carryback and carryforward periods available. The long carryback and carryforward periods permitted under the tax law are objectively verified positive evidence.
|
|
•
|
Tax planning strategies. Tax planning strategies can be, depending on their nature, heavily-weighted sources of objectively verifiable positive evidence when the strategies are available and can be reasonably executed. The Company considers tax planning strategies only if they are feasible and justifiable considering its current operations and its strategic plan. Tax planning strategies, if executed, may accelerate the recovery of a deferred tax asset so the tax benefit of the deferred tax asset can be carried back.
|
|
|
Quarter Ended
|
|
Year to Date Ended
|
||||
|
|
September 30,
2014 |
|
September 30,
2014 |
||||
|
Total insurance recoveries
|
$
|
2,058
|
|
|
$
|
2,308
|
|
|
Insurance recoveries - interruption of business
|
$
|
765
|
|
|
$
|
925
|
|
|
Less: out-of-pocket expenses related to interruption of business in
Cost of Sales
|
118
|
|
|
328
|
|
||
|
Net reduction to
Cost of sales
|
$
|
647
|
|
|
$
|
597
|
|
|
|
|
|
|
||||
|
Insurance recoveries - property damage
|
$
|
1,293
|
|
|
$
|
1,383
|
|
|
Less: Net book value of property loss in
Insurance Recoveries
|
—
|
|
|
160
|
|
||
|
Insurance recoveries
|
$
|
1,293
|
|
|
$
|
1,223
|
|
|
|
|
Quarter Ended
|
|
Year to Date Ended
|
||||||||||||
|
|
|
September 30,
2014 |
|
September 30,
2013 |
|
September 30,
2014 |
|
September 30,
2013 |
||||||||
|
Net Sales to Customers
|
|
|
|
|
|
|
|
|
||||||||
|
Distillery products
|
|
$
|
63,700
|
|
|
$
|
66,059
|
|
|
$
|
194,035
|
|
|
$
|
200,775
|
|
|
Ingredient solutions
|
|
13,815
|
|
|
14,112
|
|
|
43,043
|
|
|
44,997
|
|
||||
|
Other
(i)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
198
|
|
||||
|
Total
|
|
77,515
|
|
|
80,171
|
|
|
237,078
|
|
|
245,970
|
|
||||
|
Depreciation and Amortization
|
|
|
|
|
|
|
|
|
||||||||
|
Distillery products
|
|
2,133
|
|
|
2,064
|
|
|
6,334
|
|
|
6,102
|
|
||||
|
Ingredient solutions
|
|
578
|
|
|
572
|
|
|
1,739
|
|
|
1,742
|
|
||||
|
Other
(i)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
21
|
|
||||
|
Corporate
|
|
382
|
|
|
368
|
|
|
1,129
|
|
|
1,090
|
|
||||
|
Total
|
|
3,093
|
|
|
3,004
|
|
|
9,202
|
|
|
8,955
|
|
||||
|
Income (Loss) from Continuing Operations before Income Taxes
|
|
|
|
|
|
|
|
|
||||||||
|
Distillery products
|
|
6,547
|
|
|
(1,647
|
)
|
|
17,963
|
|
|
5,836
|
|
||||
|
Ingredient solutions
|
|
1,082
|
|
|
1,279
|
|
|
2,828
|
|
|
3,944
|
|
||||
|
Other
(i)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(90
|
)
|
||||
|
Corporate
|
|
(2,570
|
)
|
|
(5,938
|
)
|
|
(5,681
|
)
|
|
(15,620
|
)
|
||||
|
Total
|
|
$
|
5,059
|
|
|
$
|
(6,306
|
)
|
|
$
|
15,110
|
|
|
$
|
(5,930
|
)
|
|
|
|
As of September 30, 2014
|
|
As of December 31, 2013
|
||||
|
Identifiable Assets
|
|
|
|
|
||||
|
Distillery products
|
|
$
|
95,052
|
|
|
$
|
97,875
|
|
|
Ingredient solutions
|
|
24,043
|
|
|
24,954
|
|
||
|
Other
(i)
|
|
—
|
|
|
—
|
|
||
|
Corporate
|
|
30,014
|
|
|
28,500
|
|
||
|
Total
|
|
$
|
149,109
|
|
|
$
|
151,329
|
|
|
|
|
Quarter Ended
|
|
Year to Date Ended
|
||||||||||||
|
|
|
September 30,
2014 |
|
September 30,
2013 |
|
September 30,
2014 |
|
September 30,
2013 |
||||||||
|
Service cost
|
|
$
|
14
|
|
|
$
|
32
|
|
|
$
|
58
|
|
|
$
|
96
|
|
|
Interest cost
|
|
34
|
|
|
41
|
|
|
116
|
|
|
123
|
|
||||
|
Amortization of prior service cost
|
|
(66
|
)
|
|
(162
|
)
|
|
(305
|
)
|
|
(485
|
)
|
||||
|
Amortization of net actuarial loss
|
|
7
|
|
|
7
|
|
|
12
|
|
|
21
|
|
||||
|
Prior service cost recognized due to current curtailment
|
|
—
|
|
|
—
|
|
|
(52
|
)
|
|
—
|
|
||||
|
Total post-retirement benefit cost / (income)
|
|
$
|
(11
|
)
|
|
$
|
(82
|
)
|
|
$
|
(171
|
)
|
|
$
|
(245
|
)
|
|
|
|
Quarter Ended
|
|
Year to Date Ended
|
||||||||||||
|
|
|
September 30,
2014 |
|
September 30,
2013 |
|
September 30,
2014 |
|
September 30,
2013 |
||||||||
|
Interest cost
|
|
$
|
22
|
|
|
$
|
21
|
|
|
$
|
66
|
|
|
$
|
62
|
|
|
Expected return on plan assets
|
|
(26
|
)
|
|
(29
|
)
|
|
(78
|
)
|
|
(86
|
)
|
||||
|
Amortization of net actuarial loss
|
|
5
|
|
|
17
|
|
|
15
|
|
|
50
|
|
||||
|
Total pension benefit cost
|
|
$
|
1
|
|
|
$
|
9
|
|
|
$
|
3
|
|
|
$
|
26
|
|
|
Stock options granted but not exercised
|
10,000
|
|
|
Restricted stock to non-employees (authorized but not granted)
|
20,493
|
|
|
Restricted stock to employees and executives (authorized but not granted)
|
404,349
|
|
|
Total
|
434,842
|
|
|
|
|
(i)
|
|
(ii)
|
|
(iii) = (i) - (ii)
|
||||||
|
Description
|
|
Gross
Amounts of
Recognized
Assets
(Liabilities)
|
|
Gross
Amounts
offset in the
Balance Sheet
|
|
Net Amounts of
Assets (Liabilities)
presented in the
Balance Sheet
|
||||||
|
|
|
|
|
|
|
|
||||||
|
September 30, 2014
|
|
|
|
|
|
|
||||||
|
Investment in bonds
|
|
$
|
7,000
|
|
|
$
|
7,000
|
|
|
$
|
—
|
|
|
Capital lease obligation
|
|
$
|
(7,000
|
)
|
|
$
|
(7,000
|
)
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
||||||
|
December 31, 2013
|
|
|
|
|
|
|
||||||
|
Investment in bonds
|
|
$
|
7,000
|
|
|
$
|
7,000
|
|
|
$
|
—
|
|
|
Capital lease obligation
|
|
$
|
(7,000
|
)
|
|
$
|
(7,000
|
)
|
|
$
|
—
|
|
|
|
Quarter Ended
|
|
Year to Date Ended
|
||||||||||||
|
|
September 30, 2014
|
|
September 30, 2013
|
|
September 30, 2014
|
|
September 30, 2013
|
||||||||
|
Balance at beginning of period
|
$
|
547
|
|
|
$
|
83
|
|
|
$
|
1,142
|
|
|
$
|
126
|
|
|
Provision for additional expense
|
—
|
|
|
—
|
|
|
313
|
|
|
1
|
|
||||
|
Payments and adjustments
|
(313
|
)
|
|
(16
|
)
|
|
(1,221
|
)
|
|
(60
|
)
|
||||
|
Balance at end of period
|
$
|
234
|
|
|
$
|
67
|
|
|
$
|
234
|
|
|
$
|
67
|
|
|
|
|
Quarter Ended
|
|
Year to Date Ended
|
||||||||||||
|
|
|
September 30,
2014 |
|
September 30,
2013 |
|
September 30,
2014 |
|
September 30,
2013 |
||||||||
|
Distillery Products
|
|
|
|
|
|
|
|
|
||||||||
|
Net Sales
|
|
$
|
63,700
|
|
|
$
|
66,059
|
|
|
$
|
194,035
|
|
|
$
|
200,775
|
|
|
Pre-Tax Income (Loss)
|
|
6,547
|
|
|
(1,647
|
)
|
|
17,963
|
|
|
5,836
|
|
||||
|
Ingredient Solutions
|
|
|
|
|
|
|
|
|
||||||||
|
Net Sales
|
|
13,815
|
|
|
14,112
|
|
|
43,043
|
|
|
44,997
|
|
||||
|
Pre-Tax Income
|
|
1,082
|
|
|
1,279
|
|
|
2,828
|
|
|
3,944
|
|
||||
|
Other
|
|
|
|
|
|
|
|
|
||||||||
|
Net Sales
|
|
—
|
|
|
—
|
|
|
—
|
|
|
198
|
|
||||
|
Pre-Tax Loss
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(90
|
)
|
||||
|
|
|
September 30,
2014 |
|
December 31,
2013 |
||||
|
Cash and cash equivalents
|
|
$
|
—
|
|
|
$
|
2,857
|
|
|
Working capital
|
|
39,097
|
|
|
37,736
|
|
||
|
Credit facility, notes payable and long-term debt outstanding
|
|
16,663
|
|
|
23,168
|
|
||
|
Amounts available under lines of credit
|
|
36,929
|
|
|
23,920
|
|
||
|
Stockholders’ equity
|
|
96,997
|
|
|
81,603
|
|
||
|
|
|
Year to Date Ended
|
||||||
|
|
|
September 30, 2014
|
|
September 30, 2013
|
||||
|
Depreciation and amortization
|
|
$
|
9,202
|
|
|
$
|
8,955
|
|
|
Capital expenditures
|
|
4,920
|
|
|
3,571
|
|
||
|
Cash flows from operations
|
|
8,755
|
|
|
4,004
|
|
||
|
|
|
Year to Date Ended
|
||||||
|
|
|
September 30, 2014
|
|
September 30, 2013
|
||||
|
Cash Flows from Operating Activities
|
|
|
|
|
||||
|
Net income (loss)
|
|
$
|
16,112
|
|
|
$
|
(4,568
|
)
|
|
Adjustments to Reconcile Net Income (Loss) to Net Cash Provided by Operating Activities:
|
|
|
|
|
||||
|
Depreciation and amortization
|
|
9,202
|
|
|
8,955
|
|
||
|
Gain on sale of bioplastics manufacturing business
|
|
—
|
|
|
(1,453
|
)
|
||
|
Gains on property insurance recoveries
|
|
(1,223
|
)
|
|
—
|
|
||
|
Release of valuation allowance for deferred tax assets
|
|
(1,215
|
)
|
|
—
|
|
||
|
Share based compensation
|
|
588
|
|
|
970
|
|
||
|
Equity method investment (earnings) loss
|
|
(7,287
|
)
|
|
962
|
|
||
|
Changes in Operating Assets and Liabilities:
|
|
|
|
|
||||
|
Restricted cash
|
|
—
|
|
|
12
|
|
||
|
Receivables, net
|
|
(3,729
|
)
|
|
3,529
|
|
||
|
Inventory
|
|
3,452
|
|
|
(342
|
)
|
||
|
Prepaid expenses
|
|
(587
|
)
|
|
(541
|
)
|
||
|
Refundable income taxes
|
|
241
|
|
|
16
|
|
||
|
Accounts payable
|
|
(8,188
|
)
|
|
(509
|
)
|
||
|
Accounts payable to affiliate, net
|
|
2,220
|
|
|
(3,491
|
)
|
||
|
Accrued expenses
|
|
(295
|
)
|
|
1,478
|
|
||
|
Deferred credit
|
|
334
|
|
|
(340
|
)
|
||
|
Accrued retirement health and life insurance benefits and other noncurrent liabilities
|
|
(456
|
)
|
|
(680
|
)
|
||
|
Other
|
|
(414
|
)
|
|
6
|
|
||
|
Net cash provided by operating activities
|
|
$
|
8,755
|
|
|
$
|
4,004
|
|
|
•
|
Receivables increased
$3,729
for the year to date period ended
September 30, 2014
compared to a decrease of
$3,529
for the year to date period ended
September 30, 2013
. The resulting change was primarily due to increased sales sourced from our ICP joint venture and the timing of cash receipts.
|
|
•
|
Accounts payable decreased
$8,188
for the year to date period ended
September 30, 2014
compared to a decrease of
$509
for the year to date period ended
September 30, 2013
. The resulting change was primarily due to the settlement of accrued expenses related to the proxy contest and the timing of cash disbursements.
|
|
•
|
Accrued expenses decreased
$295
for the year to date period ended
September 30, 2014
compared to an increase of
$1,478
for the year to date period ended
September 30, 2013
. The decrease in accrued liabilities was primarily due to timing of cash disbursements related to 2013 bonus accruals.
|
|
|
|
(a) Total
Number of
Shares (or
Units)
Purchased
|
|
|
(b) Average
Price Paid
per Share (or
Unit)
|
|
|
(c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs
|
|
(d) Maximum
Number (or
Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
Programs
|
||||||
|
July 1, 2014 through July 31, 2014
|
|
7,641
|
|
(1)
|
|
$
|
8.30
|
|
(1)
|
|
—
|
|
|
$
|
—
|
|
|
August 1, 2014 through August 31, 2014
|
|
—
|
|
|
|
|
|
|
—
|
|
|
|
||||
|
September 1, 2014 through September 30, 2014
|
|
|
|
|
|
|
|
—
|
|
|
|
|||||
|
Total
|
|
7,641
|
|
|
|
|
|
|
—
|
|
|
|
||||
|
(1)
|
Aggregate number of shares repurchased to satisfy withholding tax obligations under Restricted Stock that vested during the month.
|
|
Exhibit Number
|
Description of Exhibit
|
|
3.1
|
Certificate of Amendment to Articles of Incorporation of MGP Ingredients, Inc., dated May 22, 2014
|
|
3.2
|
Amended and Restated Bylaws of MGP Ingredients, Inc., dated July 29, 2014 (Incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K filed August 4, 2014 (File number 000-17196))
|
|
*10.1
|
Employment Agreement, dated July 23, 2014, between MGP Ingredients, Inc. and Augustus C. Griffin, Chief Executive Officer
|
|
*10.2
|
Amendment 2 to Amended and Restated Credit Agreement dated August 5, 2014, between Wells Fargo Bank, National Association and MGP Ingredients, Inc., MGPI Processing, Inc., MGPI Pipeline, Inc. and MGPI of Indiana, LLC
|
|
*10.3
|
MGP Ingredients, Inc. Agreement as to Award of Restricted Stock Units Granted under the 2014 Equity Incentive Plan
|
|
*31.1
|
CEO Certification pursuant to Rule 13a-14(a)
|
|
*31.2
|
CFO Certification pursuant to Rule 13a-14(a)
|
|
*32.1
|
CEO Certification furnished pursuant to Rule 13a-14(b) and 18 U.S.C. 1350
|
|
*32.2
|
CFO Certification furnished pursuant to Rule 13a-4(b) and 18 U.S.C. 1350
|
|
*101
|
The following financial information from MGP Ingredients, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, formatted in XBRL (Extensible Business Reporting Language) includes: (i) Condensed Consolidated Balance Sheets as of September 30, 2014, and December 31, 2013, (ii) Condensed Consolidated Statements of Comprehensive Income (Loss) for the nine months ended September 30, 2014 and 2013, (iii) Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2014, and 2013, (iv) Condensed Consolidated Statement of Changes in Stockholders' Equity, and (v) the Notes to Condensed Consolidated Financial Statements.
|
|
|
|
|
*Filed herewith
|
|
|
Date:
|
November 12, 2014
|
By
|
/s/ Augustus C. Griffin
|
|
|
|
|
Augustus C. Griffin, President and Chief Executive Officer
|
|
|
|
|
|
|
Date:
|
November 12, 2014
|
By
|
/s/ Donald P. Tracy
|
|
|
|
|
Donald P. Tracy, Vice President, Finance and Chief Financial Officer
|
|
Exhibit Number
|
Description of Exhibit
|
|
3.1
|
Certificate of Amendment to Articles of Incorporation of MGP Ingredients, Inc., dated May 22, 2014
|
|
3.2
|
Amended and Restated Bylaws of MGP Ingredients, Inc., dated July 29, 2014 (Incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K filed August 4, 2014 (File number 000-17196))
|
|
*10.1
|
Employment Agreement, dated July 23, 2014, between MGP Ingredients, Inc. and Augustus C. Griffin, Chief Executive Officer
|
|
*10.2
|
Amendment 2 to Amended and Restated Credit Agreement dated August 5, 2014, between Wells Fargo Bank, National Association and MGP Ingredients, Inc., MGPI Processing, Inc., MGPI Pipeline, Inc. and MGPI of Indiana, LLC
|
|
*10.3
|
MGP Ingredients, Inc. Agreement as to Award of Restricted Stock Units Granted under the 2014 Equity Incentive Plan
|
|
*31.1
|
CEO Certification pursuant to Rule 13a-14(a)
|
|
*31.2
|
CFO Certification pursuant to Rule 13a-14(a)
|
|
*32.1
|
CEO Certification furnished pursuant to Rule 13a-14(b) and 18 U.S.C. 1350
|
|
*32.2
|
CEO Certification furnished pursuant to Rule 13a-14(b) and 18 U.S.C. 1350
|
|
*101
|
The following financial information from MGP Ingredients, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, formatted in XBRL (Extensible Business Reporting Language) includes: (i) Condensed Consolidated Balance Sheets as of September 30, 2014, and December 31, 2013, (ii) Condensed Consolidated Statements of Comprehensive Income (Loss) for the nine months ended September 30, 2014 and 2013, (iii) Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2014, and 2013, (iv) Condensed Consolidated Statement of Changes in Stockholders' Equity, and (v) the Notes to Condensed Consolidated Financial Statements.
|
|
|
|
|
*Filed herewith
|
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|